Effects of Neo40(TM) With Caffeine on Cycling Time Trial Performance
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Texas
-
Austin, Texas, United States, 78712
- The University of Texas at Austin
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Regular commuter cyclist or spin class participant
- Male (VO2max < 50) or Female (VO2max < 45)
- Healthy
- Blood pressure below 140/90
- Non-smoker
Exclusion Criteria:
- Does not cycle 2-3 times/week
- Regular consumption of performance-enhancing substances
- Type I or Type II diabetes
- Renal, hepatic or cardiac disease
- Current infectious disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Same form factor and flavor as test lozenge but contains no active ingredients
|
|
Active Comparator: Nitrate supplement with caffeine
|
Lozenge consisting of beetroot and 75 mg caffeine
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Improved Time Trial Performance
Time Frame: After 20 min steady-state cycling
|
Participants will cycle 20 min at increasing intensity: 8 min at 55% VO2max, 6 min at 65% VO2max, 6 min at 75% VO2max.
The 20 km time trial consists of rolling hills.
|
After 20 min steady-state cycling
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Improved work efficiency
Time Frame: During 20 min steady-state cycling
|
Expired gases will be collected and compared to expected VO2.
Blood will be collected prior to treatment, prior to exercise and during each cycling intensity to analyze lactate accumulation.
|
During 20 min steady-state cycling
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Lynne Kammer-Kerwick, MSE, MA, The University of Texas at Austin
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2012-05-0033
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.